Comprehensive safety assessments were performed and efficacy analyses included the proportions of patients in clinical remission ( CD Activity Index ( CDAI ) < 150 and no treatment failure ( TF ) ) , and with a clinical response ( 70 or 100 point CDAI reduction from baseline or remission and no TF ) .